Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions Group Plc LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.50 0.93% 272.00 271.50 273.00 273.50 265.00 271.50 261,618 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 86.8 10.1 4.0 68.2 586

Advanced Medical Solutions Share Discussion Threads

Showing 7226 to 7250 of 7375 messages
Chat Pages: 295  294  293  292  291  290  289  288  287  286  285  284  Older
DateSubjectAuthorDiscuss
26/9/2019
17:42
I do feel that the share price will be at the lower end of £2+ until their are some positive news on products or a new partner in the USA. The share price at these levels may attract an approach from a predator, in saying that how much is AMS valued at all IMHO.
dealit
25/9/2019
09:08
I can understand a 10% drop on the disappointing update, which would put us at c.270p. It's then up to the company to convince 'the market' just exactly what their 'Board expectations' are in performance terms. That should then underpin the share price
wetdream
20/9/2019
18:17
Better week for the share price, I wonder if the analysts have assessed AMS and maybe spoken to them and are confident that AMS will get US market back on track.
dealit
16/9/2019
08:50
Petty cash.
redartbmud
16/9/2019
07:59
Good to see this buy maybe the 1st step of the climb back North --- Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, announces that Chris Meredith, Chief Executive Officer, purchased ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares") on 13 September 2019, at a price of 224p. Chris Meredith - Chief Executive Officer 13 September 2019 buy 8,800 holding 1,503,377 increase 0.7%
dealit
16/9/2019
06:15
Looks like bigger buyers started investing back, the price is bouncing back now, so even if this recover to 250, that's 11% profit for investors
tgkg
15/9/2019
21:01
IMHO I feel that AMS will be seriously looked at as a potential takeover target at this share price level. If we are not bought by a predator it will take a considerable length of time to recover £3+.
dealit
15/9/2019
19:46
I think their first job is to reassure their major holders that they've not taken their eye off the ball. While a drop-off in Liquiband sales was flagged up in June, the consequences for the share price seem to have come as a surprise.
wetdream
15/9/2019
17:26
P/E and PEG ratios are all well and good but AMS need to get their act together in the USA bite the bullet and engage with a partner and as a matter of urgency.
dealit
15/9/2019
07:58
According to ADVFN Financials, at 226p, AMS still has a PEG Factor of 1.82. No wonder the share price took a bashing at >£3!
wetdream
14/9/2019
12:52
Generally, a high P/E ratio means that investors are anticipating higher growth in the future. The current average market P/E ratio is roughly 20 to 25 times earnings. Companies that are losing money do not have a P/E ratio. AMS fit the above categories, let us hope with good news flow we can start to climb North again
dealit
13/9/2019
10:09
Not wishing to be pedantic but I see PE as 20.3
potty punter
13/9/2019
10:06
My main concern is Trump's shouts of 'America First'. Any US company making a similar product to AMS's product will soon or already have preference with the buyers/stockists of medicals for US hospitals, IMO.
winnings1
13/9/2019
09:31
Still on an PE of circa 25/26.
zipstuck
13/9/2019
08:37
The share price today has fallen by 14 times the interim dividend due. I really don't think the tiny dividend here will affect buying decisions......
hydrus
13/9/2019
08:33
More people start buying it, it's on oversold territory plus it looks like it was natural price correction which is happening every 6 months, as dividents coming up within 2 weeks it's last chance to buy cheap
tgkg
12/9/2019
16:14
Agreed There will not be any news for a while, and the analysts will be churning out their noes to clients. Bias is bound to be negative. The price will find a stable floor, at some point. Sell out, or sit tight.
redartbmud
12/9/2019
13:47
No rush to buy. Major shareholders stay fast asleep..zzzzz
wetdream
12/9/2019
12:20
Looks like few players deliberately sell few shares to drop the price and just after they purchase it cheaper, simply visible. Someone is acquiring shares
tgkg
12/9/2019
12:03
They have a lot of cash at the moment so they are doing alright. They are fully prepared financially for any delay with products. Everyone noticed that sales dropped this year because of brexit issues. Government already spends more money on NHS, but the real spending didn't yet occur, it's only now being allocated to specific sectors of NHS so we just need to wait for it. Funding is given
tgkg
12/9/2019
12:03
They have a lot of cash at the moment so they are doing alright. They are fully prepared financially for any delay with products. Everyone noticed that sales dropped this year because of brexit issues. Government already spends more money on NHS, but the real spending didn't yet occur, it's only now being allocated to specific sectors of NHS so we just need to wait for it. Funding is given
tgkg
12/9/2019
08:42
Just shows, imho, that 'Board Expectations' and 'Market Expectations' can be quite different. Clearly, the Board 'expected' Liquiband sales to plummet in the US, but failed to alert the Market. Hence the collapse in the share price
wetdream
12/9/2019
07:55
Clearly they are issues that the company has to deal with. One part, albeit a large section, is experiencing problems, but there is growth elsewhere. Management needs to get to grips, with the problems ASAP. The big question is whether they are temporary, or permanent. Numis downgrades Advanced Medical after sales slip Numis has downgraded Advanced Medical Solutions (AMS) after a drop off in sales of the wound care company’s Liquiband surgical wound adhesive. Analyst Paul Cuddon downgraded his recommendation from ‘add’ to ‘hold’ with a target price of 290p on the stock after interims showed the company was behind on sales. The shares fell 18.2% to 230p yesterday, ‘Performance was impacted by significant declines in US sales of Liquiband, and although the broader portfolio grew 10% the weak performance of AMS’ leading brands raises concerns over the quality of the previous year’s 7% growth and the potential timing of a recovery,’ he said. ‘With the shares trading on 17 times enterprise value/earnings, we drop to “hold” awaiting more clarity on the trajectory of a potential recovery.’
redartbmud
12/9/2019
07:53
AMS IMHO were oversold yesterday. We as small investors are open to the MMs manipulating stock for various reasons. The Interims were not as good as we have come to expect from AMS, in saying that AMS still made a profit and maintained growth + increasing the dividend payment. All successful Companies have a diverse product range and have more than one market they rely on as do AMS.
dealit
11/9/2019
21:59
Tho the above destocking due to Brexit sounded a one off and now they talk about losing sales to competitors which is evidently not. Saying that at some level they become a nice takeover for a US healthcare co particularly at current exchange rates?
snape
Chat Pages: 295  294  293  292  291  290  289  288  287  286  285  284  Older
ADVFN Advertorial
Your Recent History
LSE
AMS
Advanced M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 18:43:25